Five-Year Outcomes After Endovascular Treatment for Large Vessel Occlusion Stroke

Chang‐Xiong Gong, Jiacheng Huang, Weilin Kong, Fengli Li, Chang Liu, Jie Yang, Shuai Liu, Zhongming Qiu, Min Lin, Zhangbao Guo, Zhizhong Yan, Xianjun Huang, Shuai Zhang, Wentong Ling, Peiyang Zhou, Zhen Wang, Yong Liu, Dongzhang Xue, Yaoyi Zhong, Shu Yang, Yue Wan, Jiayang Fang, Wenguo Huang, Huihui Liu, Jun Luo, Rongzhong Li, Changming Wen, Xinmin Fu, Mingyi Tu, Li Wang, Xiguang Tian, Huiyuan Peng, Zhilin Wu, Guoyong Zeng, Wenjie Zi, Qingwu YangFrontiers in Neuroscience 2022 · DOI

TL;DR

This study followed over 600 patients who underwent endovascular treatment (EVT) for large vessel occlusion (LVO) stroke for five years. It found that the positive functional outcomes achieved at 90 days were largely sustained over the five-year period, highlighting the long-term efficacy of EVT. The research also identified key predictors for long-term outcomes, emphasizing the importance of managing atrial fibrillation to reduce stroke recurrence.

What Problem Does This Paper Address?

Stroke remains a leading cause of death and disability. For acute ischemic strokes caused by large vessel occlusion (LVO) in the anterior circulation, endovascular treatment (EVT) – a procedure to physically remove the blood clot – has become a standard of care. While EVT has demonstrated significant benefits in the short term (typically assessed at 90 days), there has been a lack of comprehensive data on the long-term functional outcomes, mortality, and stroke recurrence rates in patients treated with EVT, especially in real-world settings outside of clinical trials. This gap makes it challenging to fully understand the sustained impact of EVT and to inform long-term patient management and healthcare policy.

Methods

This study employed a multicenter, observational, nationwide registry design called SUSTAIN. They collected data from 28 comprehensive stroke centers across China. The study retrospectively included consecutive patients aged 18 years or older who presented with acute anterior circulation stroke and underwent EVT for LVO.

Key aspects of their methodology include:

  • Patient Selection: Inclusion criteria focused on patients with AIS, confirmed LVO, and who underwent EVT. Exclusion criteria aimed to ensure a homogeneous study population by removing patients with significant pre-existing disability, cerebral hemorrhage, or incomplete data.
  • Procedures: EVT encompassed a range of techniques including mechanical thrombectomy, thromboaspiration, and stenting. Post-procedure management involved careful blood pressure control and antithrombotic medication protocols to prevent complications like stent thrombosis.
  • Data Collection: A comprehensive set of data was collected, including baseline characteristics, stroke risk factors, stroke severity (NIHSS), imaging findings, EVT details, complications, and outcomes.
  • Outcome Measures:
    • Primary Outcome: Proportion of patients with a good functional outcome (modified Rankin Scale score [mRS] 0-2) at 5 years.
  • Secondary Outcomes: Excellent outcome (mRS 0-1), all-cause mortality, and risk of stroke recurrence at 5 years.
  • Statistical Analysis: Multivariable logistic regression and Cox proportional hazards models were used to identify independent predictors of functional outcomes, mortality, and stroke recurrence.

Datasets

The study utilized data from the SUSTAIN registry, a nationwide registry of patients undergoing EVT for acute LVO in China. This registry collected data from 28 comprehensive stroke centers. The study included 807 patients with 90-day follow-up data and 657 patients with 5-year follow-up data. This is a real-world dataset, distinct from the highly controlled environments of randomized clinical trials.

Key Insights and Ideas

  • Sustained Efficacy of EVT: The most striking finding is that the positive functional outcomes achieved by EVT at 90 days are largely maintained over a 5-year period. This suggests that EVT provides a durable benefit, not just an acute improvement.
  • Mortality Pattern: The study highlights that the risk of death is highest in the immediate post-stroke period (within 90 days). While mortality continues, the rate significantly decreases after this initial critical phase.
  • Stroke Recurrence as a Major Threat: Stroke recurrence is a significant event, strongly correlated with increased mortality and poorer functional recovery. This underscores the critical need for effective secondary prevention strategies.
  • Predictors of Good Outcome: Younger age, a lower mRS score at 90 days, and the absence of stroke recurrence were identified as independent predictors of a good functional outcome at 5 years. This reinforces the importance of early recovery and preventing subsequent events.
  • Predictors of Mortality: Advanced age, higher mRS at 90 days, and stroke recurrence were associated with increased mortality risk at 5 years.
  • Atrial Fibrillation and Recurrence: Atrial fibrillation emerged as a significant independent predictor for stroke recurrence. This points to the crucial role of managing AF, potentially through anticoagulation, as a key strategy for long-term stroke prevention.

Key Results

  • 90-Day Outcomes: At 90 days, 27.0% of patients had an excellent outcome (mRS 0-1) and 43.2% had a favorable functional outcome (mRS 0-2). 24.7% of patients died.
  • 5-Year Outcomes: At 5 years, 28.9% of patients had an excellent outcome, and 39.7% had a good functional outcome (mRS 0-2). A substantial 48.2% of patients died by 5 years.
  • Outcome Transformation: Among patients who achieved functional independence at 90 days (mRS 0-2), 77.3% maintained this favorable outcome at 5 years.
  • Stroke Recurrence: The cumulative stroke recurrence rate at 5 years was 28.2%.
  • Predictive Factors:
    • Good Outcome: Younger age (OR 0.96), lower mRS at 90 days (OR 0.15), and no stroke recurrence (OR 0.001) were protective.
  • Mortality: Advanced age (OR 1.04), higher mRS at 90 days (OR 4.07), and stroke recurrence (OR 273.95) increased mortality risk.
  • Stroke Recurrence: Advanced age (OR 1.06), atrial fibrillation (OR 1.63), and higher mRS at 90 days (OR 0.84) were associated with increased risk.

Limitations and Future Work

The authors acknowledge several limitations:

  • Observational Design: As a registry study, it cannot establish causality as definitively as a randomized controlled trial.
  • Lack of Control Group: The study did not include a control group of patients who did not receive EVT, limiting direct comparison of EVT's benefit against standard care in this specific cohort.
  • Missing Data: While they had a substantial number of patients with 5-year follow-up, some data was missing, and multiple imputation was not used for sensitivity analysis.
  • Focus on Functional Outcome: The study primarily evaluated functional outcomes and did not assess quality of life using instruments like EQ-5D.
  • Selection Bias: The retrospective nature and selection criteria (e.g., good pre-stroke functional status) may introduce bias, meaning the results might not be generalizable to all LVO stroke patients.
  • Generalizability: The findings are specific to the Chinese population and may differ in other regions due to variations in healthcare practices, genetics, and stroke etiologies.
  • Missing Predictors: Important outcome predictors like treatment times, complications, and reperfusion success were not fully captured or analyzed.

Future work could involve:

  • Conducting prospective studies with control groups to further validate EVT's long-term efficacy.
  • Incorporating quality-of-life assessments to provide a more holistic view of patient outcomes.
  • Investigating the impact of specific EVT techniques and reperfusion strategies on long-term results.
  • Exploring more detailed strategies for managing atrial fibrillation and other modifiable risk factors to further reduce stroke recurrence.

Summary updated

Abstract

Our results indicated that the beneficial effect of EVT in patients with acute LVO can be sustained during the course of at least 5 years. Reducing the risk of stroke recurrence by anticoagulation for atrial fibrillation may be a crucial strategy to improve long-term outcome.
BibTeX
@inproceedings{gong2022five,
  author = {Chang‐Xiong Gong and Jiacheng Huang and Weilin Kong and Fengli Li and Chang Liu and Jie Yang and Shuai Liu and Zhongming Qiu and Min Lin and Zhangbao Guo and Zhizhong Yan and Xianjun Huang and Shuai Zhang and Wentong Ling and Peiyang Zhou and Zhen Wang and Yong Liu and Dongzhang Xue and Yaoyi Zhong and Shu Yang and Yue Wan and Jiayang Fang and Wenguo Huang and Huihui Liu and Jun Luo and Rongzhong Li and Changming Wen and Xinmin Fu and Mingyi Tu and Li Wang and Xiguang Tian and Huiyuan Peng and Zhilin Wu and Guoyong Zeng and Wenjie Zi and Qingwu Yang},
  title = {{Five-Year Outcomes After Endovascular Treatment for Large Vessel Occlusion Stroke}},
  booktitle = {Frontiers in Neuroscience},
  year = {2022},
  doi = {10.3389/fnins.2022.920731},
}
Figure